NCT05663866 2026-04-13Premedication to Reduce Amivantamab Associated Infusion Related ReactionsJanssen Research & Development, LLCPhase 2 Active not recruiting68 enrolled 12 charts
NCT05096663 2025-05-15Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)SWOG Cancer Research NetworkPhase 2/3 Active not recruiting82 enrolled